BBOT (BridgeBio Oncology Therapeutics) Buyback Yield %: 0.00 (As of Jul. 13, 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.32
View Full Analysis

What is BridgeBio Oncology Therapeutics Buyback Yield %?

BridgeBio Oncology Therapeutics BBOT -8.72% 12 Buyback Yield % is 0.00 as of Jul. 13, 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 742 Biotechnology companies, BridgeBio Oncology Therapeutics ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BridgeBio Oncology Therapeutics's current buyback yield was 0.00%.

BridgeBio Oncology Therapeutics Buyback Yield % Related Terms

BridgeBio Oncology Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Buyback Yield % Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BBOT vs FTH, MNPR, MDXG: Buyback Yield % Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Oncology Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's Buyback Yield % falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BridgeBio Oncology Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 1001.49984
=0.00%

BridgeBio Oncology Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 716.79655
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
BridgeBio Oncology Therapeutics (BBOT) has a Buyback Yield % of 0.00 as of Jul. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 742 companies in the Biotechnology industry.
Is BridgeBio Oncology Therapeutics' Buyback Yield % too high?
BridgeBio Oncology Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Buyback Yield % compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 742 companies for Buyback Yield %. This places BridgeBio Oncology Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Buyback Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.32
Price